story of the week
Quality-of-Life Comparable Between Cabozantinib and Everolimus in Metastatic Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
J. Clin. Oncol 2018 Jan 29;[EPub Ahead of Print], D Cella, B Escudier, NM Tannir, T Powles, F Donskov, K Peltola, M Schmidinger, DYC Heng, PN Mainwaring, HJ Hammers, JL Lee, BJ Roth, F Marteau, P Williams, J Baer, M Mangeshkar, C Scheffold, TE Hutson, S Pal, RJ Motzer, TK ChoueiriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.